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Summary Objectives: To analyze the antimicrobial susceptibility of Acinetobacter
spp. isolates collected from Latin American medical centers as part of the SENTRY An-
timicrobial Surveillance Program and also to evaluate the dissemination of multi-drug
resistant Acinetobacter spp. strains in the region.
Methods: A total of 826 isolates of Acinetobacter spp. from multiple infection sites
were collected from January 1997 to December 2001 in ten medical centers and sus-
ceptibility tested to >25 selected agents by broth microdilution. Multi-drug resistant
Acinetobacter spp. isolates were molecular typed.
Results: Resistance rates to carbapenems varied signiﬁcantly among countries. A
continued annual increase occurred in the Argentinean medical centers. In contrast,
carbapenem resistance was rare in Chilean centers, and decreased signiﬁcantly in the
Brazilian institutions. Acinetobacter spp. isolates recovered from lower respiratory
tract and bloodstream infections were associated with lower antimicrobial suscepti-
bility rates. Resistance rates to imipenem were higher among isolates collected from
intensive care units (13.5%) than among isolates from other units. A major ribogroup
pattern (521-1) was detected among eight Acinetobacter spp. strains isolated from
three distinct Latin American countries.
Conclusions: This study found that antimicrobial resistance is still a major issue
among Acinetobacter spp. isolates collected from some Latin American countries.
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The dissemination of a major bacterial cluster in different regions reinforces the
importance of longitudinal surveillance programs, such as SENTRY, as valuable tools
for monitoring antimicrobial susceptibility rates and guiding local interventions.
© 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
Introduction
Acinetobacter spp. represents an important cause
of nosocomial infections, including pneumonia,
bacteremia, and meningitis. These opportunistic
organisms have emerged as pathogens, especially
among critically ill patients.1 Resistance rates to
ﬂuoroquinolones, aminoglycosides, cephalosporins,
and ureidopenicillins are high in several regions. Al-
though carbapenems remain the mainstay of ther-
apy for severe suspected Acinetobacter infections,
resistance to this antimicrobial class has been in-
creasingly reported. Thus, therapeutic options can
become markedly limited.2—4
Major hospital outbreaks related to multi-drug
resistant (MDR) Acinetobacter spp. have been re-
cently described in several countries,5—7 making
surveillance of antimicrobial susceptibility an im-
portant public health task. Although limited data
on the antimicrobial susceptibility of Acinetobac-
ter spp. available, previous studies have demon-
strated that isolates from the Latin American region
are considerably less susceptible to antimicrobial
agents than isolates collected from either North
America or Europe.8,9
This study was undertaken to determine the fre-
quency of occurrence and the antimicrobial suscep-
tibility of Acinetobacter spp., as well as to deter-
mine the possibility of the spreading of MDR iso-
lates among the Latin American medical centers
participating of the SENTRY Antimicrobial Surveil-
lance Program.
Material and methods
Study design
The SENTRY Antimicrobial Surveillance Program
monitors the frequency of occurrence and antimi-
crobial resistance patterns of pathogens causing
nosocomial and community-acquired infections
worldwide. Participating countries in Latin Amer-
ica included Argentina (1997—2001); Brazil (1997—
2001); Chile (1997—2001); Colombia (1997—2000);
Mexico (1997—2001); Uruguay (1997 only) and
Venezuela (1998—2001). Isolates were considered
to be clinically signiﬁcant based on the evaluation
of the local physicians. In this study, all isolates
were collected from hospitalized patients and only
one isolate per patient was included. The moni-
tored body sites of infections were bloodstream,
lower respiratory tract, skin and soft tissue, and
urinary tract.8,9
Identiﬁcation and susceptibility tests
The isolates were identiﬁed at the participating
institutions by the routine methodology in use at
each laboratory and forwarded to the coordinator
laboratory (Iowa, USA). Upon receipt at the co-
ordinator laboratory, isolates were subcultured on
blood agar to ensure viability and purity. Species
identiﬁcations were conﬁrmed with the use of the
Vitek system (bioMérieux Vitek®, Hazelwood, MO)
or API (bioMérieux Vitek®, Hazelwood, MO) or stan-
dard reference methods when needed. Protocols
for species identiﬁcation upon receipt at the coor-
dinator center were previously described.9 Antimi-
crobial susceptibility testing of isolates was per-
formed by reference broth microdilution methods
as described by the National Committee for Clinical
Laboratory Standards (NCCLS).10 Microdilution trays
were purchased from TREK Diagnostic Systems Inc.
(Westlake, OH, USA). Antimicrobial agents were ob-
tained from their respective manufacturers.
Tested antimicrobial agents included amikacin,
cefepime, ceftazidime, ciproﬂoxacin, gatiﬂoxacin,
gentamicin, imipenem, levoﬂoxacin, meropenem,
piperacillin, piperacillin/tazobactam, polymyxin
B, ticarcillin, ticarcillin/clavulanic acid, tetracy-
cline, and tobramycin. Antimicrobial susceptibility
testing was performed according to the reference
broth microdilution method recommended by the
NCCLS.10,11 Quality control was performed by test-
ing Escherichia coli ATCC 25922, Staphylococcus
aureus ATCC 29213, Pseudomonas aeruginosa ATCC
27853, and Enterococcus faecalis ATCC 29212.
Ribotyping
Thirty-nine MDR Acinetobacter isolates recovered
from unique patients with bloodstream infections
hospitalized at distinct intensive care units (ICUs)
from seven different Latin American medical cen-
ters located in Argentina, Brazil, Chile, and Colom-
bia were randomly selected for rybotyping. The
isolates were ribotyped using the RiboPrinter® Mi-
crobial Characterization System (Qualicon, Wilm-
ington, DE).
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Chromosomal DNA was digested with EcoRI and
the DNA fragments were then hybridized with a la-
beled DNA probe.12 The bands were detected us-
ing chemiluminescent substrate and the image was
captured using a customized CCD camera and elec-
tronically transferred to the computer system. Each
lane of sample data was normalized to a standard
marker set and band intensity. This normalized out-
put was compared with all previously run samples
and reference patterns. Similarity coefﬁcients were
calculated based on both position and relative band
weight. Isolates were considered to have the same
RiboPrinter® pattern, ribotype, if the similarity co-
efﬁcient between their patterns was ≥0.90.12
Data analysis
Differences in group proportions were assessed with
the Chi-square and Fisher’s exact tests. Two-tailed
tests of signiﬁcance at the p ≤ 0.05 level were
used to determine statistical signiﬁcance. Statis-
tical analysis was performed with Epi-Info version
6.04b software package (Centers for Disease Con-
trol and Prevention, Atlanta, GA).
Results
A total of 826 Acinetobacter isolates were collected
between January 1997 and December 2001. Brazil
contributed the largest number of isolates (n= 400)
Table 1 Antimicrobial susceptibility of Acinetobacter spp. isolates in Latin America as reported in the SENTRY
Antimicrobial Surveillance Program, 1997—2001.
Antimicrobial
agents
% susceptible by year (n tested) MIC (g/ml)
1997 (193) 1998 (215) 1999 (129) 2000 (123) 2001 (166) Total (826) MIC50 MIC90
Meropenem 91.3 87.0 89.1 82.9 81.9 86.8 2 >8
Imipenem 91.2 87.0 88.4 82.9 83.7 86.9 1 >8
Cefepime 33.7 27.4 48.8 38.2 30.4 35.2 >16 >16
Ceftazidime 29.0 17.7 37.2 35.0 45.8 28.5 >16 >16
Piperacillin 18.1 11.6 26.4 18.7 17.5 17.7 >128 >128
Piperacillin-
tazobactam
24.9 19.5 36.4 30.1 27.7 26.6 >64 >64
Ticarcillin 23.8 14.4 30.2 22.0 19.9 20.2 >128 >128
Ticarcillin-
clavulanate
19.2 20.0 32.6 28.5 23.5 24.8 >128 >128
Ciproﬂoxacin 27.5 29.3 34.9 35.8 28.3 30.5 1 >4
Levoﬂoxacin 29.0 30.7 37.2 39.8 28.9 32.3 >4 >4
Gatiﬂoxacin 30.6 34.0 41.1 39.8 30.1 34.4 4 >4
Tetracycline 68.4 49.8 52.7 46.7 33.7 50.9 8 >8
Amikacin 35.8 27.0 37.2 35.0 38.0 34.0 >32 >32
Gentamicin 33.7 30.2 40.3 31.7 30.7 32.9 >8 >8
Tobramycin 35.8 40.5 51.2 — 45.8 41.5 16 >16
Polymyxin B — — — — 96.4 96.4a ≤1 2
a Isolates exhibiting MICs ≤2g/ml were considered susceptible to polymyxin B.13
followed by Argentina (185); Chile (102); Venezuela
(58); Colombia (43); Uruguay (20); and Mexico
(18). The majority of isolates were identiﬁed as
A. calcoaceticus-baumannii complex (85.3%) while
9.5% of isolates were not identiﬁed to the species
level. Other, less frequently isolated, species in-
cluded Acinetobacter lwofﬁi (5.0%) and A. junii
(0.2%). The number of isolates and their respec-
tive susceptibility proﬁle according to the year of
isolation are shown in Table 1. Overall, the highest
susceptibility rates were achieved by meropenem
(86.8%) and imipenem (86.9%). However, a signif-
icant decrease in the carbapenem susceptibility
rates was noticed throughout the study period.
Isolates recovered in 2001 were considerably more
resistant to imipenem (p = 0.02; OR: 2.01, 95% CI:
1.01—4.03) and meropenem (p = 0.006; OR=2.13,
95% CI: 1.16—4.53), when compared to those col-
lected in 1997. Other -lactams showed poor in
vitro activity against the isolates tested, with sus-
ceptibility rates ranging from 17.7% (piperacillin)
to 35.2% (cefepime). Similarly, the tested ﬂuo-
roquinolones (ciproﬂoxacin, gatiﬂoxacin and lev-
oﬂoxacin) demonstrated low susceptibility rates
(<40.0%). Polymyxin B showed excellent activity
(MIC50, ≤1g/ml; 96.4% susceptibility), but this
compound was only evaluated against pathogens
collected in 2001. Six isolates categorized as resis-
tant to polymyxin B (MIC ≥4g/ml)13 were recov-
ered from hospitalized patients with bloodstream
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Table 2 Susceptibility of Acinetobacter spp. isolates to carbapenems in selected Latin American countries as
reported in the SENTRY Antimicrobial Surveillance Program, 1997—2001.
Country/yeara
(n tested)
Imipenem Meropenem
MIC50/MIC90 % Susceptible % Resistant MIC50/MIC90 % Susceptible % Resistant
Argentina
1997 1/2 97.7 0.0 1/4 97.7 0.0
1998 1/ >8 84.8 15.2 2/ >8 82.6 15.2
1999 1/2 95.2 0.0 2/2 95.2 0.0
2000 2/ >8 60.0 40.0 4/ >8 60.0 37.1
2001 1/ >8 60.0 40.0 2/ >8 57.5 32.5
Total (185) 1/ >8 78.9 20.0 2/ >8 78.4 17.8
Brazil
1997 1/ >8 77.8 13.6 1/ >8 84.0 14.8
1998 1/ >8 85.6 12.5 1/ >8 87.5 12.5
1999 0.5/2 95.5 4.5 1/2 95.5 3.0
2000 0.5/ >2 91.4 8.6 1/4 91.4 5.2
2001 0.5/ >2 97.8 2.2 2/4 96.7 3.3
Total (400) 1/4 90.8 8.5 1/4 90.8 8.3
Chile
1997 0.5/8 96.7 3.3 1/4 100.0 0.0
1998 1/2 100.0 0.0 2/4 94.3 2.9
1999 0.5/2 100.0 0.0 0.5/2 100.0 0.0
2000 0.12/ >2 100.0 0.0 0.25/2 100.0 0.0
2001 0.5/2 100.0 0.0 2/ >8 95.5 4.5
Total (102) 0.5/2 98.0 0.7 2/4 96.1 2.0
Colombiab
1997 0.5/ >8 87.5 12.5 0.5/8 87.5 12.5
1998 1/ >8 80.0 20.0 1/2 90.0 10.0
1999 0.5/2 75.0 25.0 1/ >8 75.0 25.0
2000 0.12/ >0.25 100.0 0.0 1/4 100.0 0.0
Total (43) 0.25/ >8 86.0 14.0 1/8 88.4 9.3
a Includes only countries contributing more than 40 isolates.
b Colombian medical center did not participate in the SENTRY Program in 2001.
infections from three different Brazilian medical
centers and only one of those was also resistant to
carbapenems.
Table 2 shows the prevalence of Acinetobac-
ter isolates resistant to carbapenems isolated
in selected Latin American countries. Overall,
the highest resistance rate to imipenem was de-
tected in Argentina (20.0%), followed by Colombia
(14.0%) and Brazil (8.5%). In Brazil, imipenem re-
sistance rates decreased signiﬁcantly during the
ﬁve-year period, from 13.6% in 1997 to 2.2% in 2001
(p = 0.001, chi-square for trend test). Carbapenem
resistance was not detected in the Mexican and
Uruguayan medical centers (data not shown), but
these institutions contributed small numbers of iso-
lates (<40) in the evaluated period. Resistance to
imipenem was found to be rare in Chilean centers,
with 98.0% of isolates susceptible to this antimicro-
bial. Actually, no isolate resistant to the evaluated
carbapenems could be detected in Chile in the
last four years of the study (1998—2001). Although
the mean resistance to imipenem in Argentina was
20% over the ﬁve-year period, an increasing resis-
tance rate (40% resistance) was documented in the
last two years of the study. Moreover, resistance
rates to carbapenems in Argentina (2000 and 2001)
were signiﬁcantly higher than those displayed by
other Latin American nations in the same period
(p < 0.05).
Resistance rates to carbapenems were also higher
among isolates recovered from the lower respira-
tory tract (9.2—19.6%) than among those isolated
from the bloodstream (5.7—17.2%) skin/soft tissue
(11.0—13.7%) or the urinary tract (0.0%) (Table 3).
Imipenem resistance rates were at least two-fold
higher among isolates from intensive care units
(ICU) when compared to non-ICU isolates (13.5%
vs. 6.4%; p < 0.001) (Table 4).
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Table 3 Antimicrobial susceptibility of Acinetobacter spp. isolates to imipenem and meropenem according to
the site of infection as reported in the SENTRY Antimicrobial Surveillance Program, Latin America 1997—2001.
Infection site/Year
(n tested)a
Imipenem Meropenem
MIC50/MIC90 % Susceptible % Resistant MIC50/MIC90 % Susceptible % Resistant
Bloodstream
1997 (87) 0.5/2 92.0 6.9 1/4 93.1 5.7
1998 (107) 1/8 89.7 8.4 1/4 91.6 7.5
1999 (61) 0.5/2 90.2 8.2 1/2 91.8 8.2
2000 (58) 0.5/ >8 82.8 17.2 1/ >8 82.8 12.1
2001 (67) 0.5/ >8 88.1 10.4 1/ >8 85.1 11.9
Lower respiratory tract
1997 (65) 1/8 89.2 9.2 1/8 89.2 9.2
1998 (75) 1/ >8 81.3 18.7 2/ >8 78.7 18.7
1999 (48) 1/ >8 89.6 10.4 1/8 89.6 8.3
2000 (51) 0.5/ >8 80.4 19.6 2/ >8 80.4 19.6
2001 (60) 1/ >8 86.7 13.3 2/ >8 85.0 13.3
a Includes only infection sites with more than 100 isolates over the study period. A total of 35 and 74 Acinetobacter
spp. isolates were collected, respectively, from skin/soft tissue and urinary tract infections.
Table 4 Carbapenem susceptibility of Acinetobacter spp. isolates from intensive care unitsa as reported in the
SENTRY Antimicrobial Surveillance Program, Latin America, 1997—2001.
Intensive care unit (415 isolates)a Non-intensive care unit (264 isolates)a
MIC50/MIC90 % Susceptible % Resistant MIC50/MIC90 % Susceptible % Resistant
Imipenem 1/ >8 85.1% 13.5% 0.5/2 92.8% 6.4%
Meropenem 2/ >8 84.8% 13.0% 1/4 92.4% 6.1%
a The origin of 147 isolates was not known.
Eighteen different ribotyping patterns were iden-
tiﬁed among the 39 Acinetobacter spp. isolates
evaluated (Table 5). The most frequent ribotype
was 521-1, which was detected among eight iso-
lates from three medical centers located in Ar-
gentina, Brazil, and Colombia. Six other ribotypes
were detected in more than one medical center,
and two of them were detected in medical centers
located in different countries (Table 5).
Table 5 Distribution of ribotypes found in more than one Acinetobacter spp. isolate according to medical center
and nation as reported in the SENTRY Antimicrobial Surveillance Program, 1997—2001.
Ribotype No. of isolates Medical center (No. of isolates) Nations
521-1 8 40(5); 44(1); 48(2) Argentina, Brazil, Colombia
531-3 4 41(1); 42(1); 46(1); 48(1) Brazil, Chile
815-2 4 39(2); 40(1); 46(1) Argentina, Brazil
1008-2 3 48(3) Brazil
1242-5 3 46(1), 48(2) Brazil
218-1 2 46(1); 48(1) Brazil
1380-1 2 46(1); 48(1) Brazil
1414-5 2 46(2) Brazil
1395-4 2 42(2) Chile
Discussion
Acinetobacter spp. is generally an opportunistic
nosocomial pathogen often resistant to multiple
therapeutic agents.1 In the present study we eval-
uated the susceptibility proﬁle of Acinetobacter
spp. isolates to selected antimicrobials in Latin
American centers as part of a global surveillance
program. Our study results were similar to previous
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reports that showed a decreased antimicrobial sus-
ceptibility proﬁle for Acinetobacter spp. isolates in
the Latin American region.14,15
Overall, resistance rates were very high for most
antimicrobial agents, with the exception of the
carbapenems, (imipenem and meropenem) and
polymyxin B. Among clinical isolates of Acine-
tobacter spp., several antimicrobial resistance
mechanisms have been described, including the
production of chromosomally- or plasmid-mediated
-lactamase, aminoglycoside-modifying enzymes
and alteration in the outer membrane permeabi-
lity.16,17 Although quinolones were initially con-
sidered promising antimicrobial agents to treat
Acinetobacter infections, these compounds did
not show adequate coverage against this pathogen
in the Latin American region.18 These data were
also in agreement with previous studies, which
demonstrated that quinolone resistance has rapidly
emerged among Acinetobacter spp. clinical iso-
lates, probably reﬂecting the ability of this
pathogen to acquire resistance determinants via
several mechanisms.17
Although polymyxin B was very active against
Acinetobacter spp. isolates, emerging resistance
to this compound has been reported especially in
Brazil.19,20 This fact is very worrisome, since very
few therapeutic options are clinically available to
treat infections caused by this multi-drug resistant
pathogen.
Isolates recovered from SENTRY participant cen-
ters in North America and Europe have demon-
strated markedly higher susceptibility rates to
carbapenems and quinolones.21 In this study,
the antimicrobial susceptibility of Acinetobac-
ter spp. varied signiﬁcantly among Latin Amer-
ican countries, among centers and even among
wards of a given hospital (ICU versus non-ICU).
These discrepancies may reﬂect differences in
the environmental factors and also in patterns
of local antimicrobial usage or infection control
policies.9,22
There has been a consensus that hospitalization
in ICU is an important factor inﬂuencing emergence
of antimicrobial resistance.23 This pattern was
corroborated by this study, which demonstrates
higher rates of carbapenem-resistant Acinetobac-
ter spp. in these high-risk units.
Molecular typing results clearly indicate clonal
dissemination of multi-drug resistant strains of
Acinetobacter spp. Inter-hospital dissemination
could be identiﬁed in Argentina and Brazil through
the presence of identical or similar ribotypes in dis-
tinct institutions in the same country. In addition,
the ﬁnding of isolates with an identical ribotype
(521-1) in medical centers from different countries
may indicate the international spread of multi-drug
resistant (MDR) clones. The wide dissemination
of MDR pathogens has already been documented
for other organisms in Latin America and may in-
dicate that control measures should be designed
to avoid the greater worldwide dissemination of
these bacteria harboring important mechanisms of
resistance.24
In addition to clonal dissemination, selection
of other resistant mutants was indicated by the
genetic diversity found among evaluated MDR iso-
lates. In fact, the Brazilian institutions harbored
most of the distinct resistant genotypes, espe-
cially clustered in two medical centers (46 and
48). This indicates that antimicrobial use policies
must be reviewed and appropriate interventions
implemented in the respective institutions. Nev-
ertheless, the data have some limitations that are
inherent to laboratory-based surveys. The small
number of Acinetobacter spp. isolates collected
and tested from some Latin American countries
may have inﬂuenced the susceptibility and typ-
ing results, especially in countries that submit-
ted a small number of isolates, such as Mexico,
Venezuela, and Colombia. Further studies, testing
a larger number of Acinetobacter spp. isolates,
are necessary in these regions to address such
questions.
Emergence of resistance to multiple antimi-
crobial agents among Acinetobacter spp. isolates
has become a major international public health
problem.16,25 The geographic variation of resis-
tance patterns emphasizes the importance of local
surveillance in determining the most adequate
therapy for Acinetobacter spp. infections.26,27
Epidemiology-based surveillance studies, such
as SENTRY, have a crucial role in disseminat-
ing important up-to-date local data to guide the
correct management of antimicrobial prescrib-
ing strategies in the nosocomial and community
environment.
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